The Efficacy of On-Site Integration Screening and Microelimination Programs for Chronic Hepatitis C in a Detection Center: A Comparison of the Treatment Outcomes and Characteristics of Incarcerated Patients and Outpatients

Table 1

Baseline characteristics: sporadic outpatient HCV therapy (control group) vs. incarcerated patients (incarcerated group).

Characteristics	Control ()	Incarcerated ()	value
Age (years)	49.0 (41.0, 58.0)	47.0 (42.0, 53.0)	0.4851
HCV genotype (%)			0.0008
1a	14 (18.92)	8 (21.62)
1b	12 (16.22)	6 (16.22)
2	30 (40.54)	4 (10.81)
3	3 (4.05)	6 (16.22)
6	14 (18.92)	7 (18.92)
Mixed	0	4 (10.81)
Indeterminate	1 (1.35)	2 (5.41)
Fibrosis-4 score (%)			0.2234
F0	32 (43.24)	22 (59.46)
F1	17 (22.97)	10 (27.03)
F2	11 (14.86)	2 (5.41)
F3	9 (12.16)	1 (2.70)
F4	5 (6.76)	2 (5.41)
Liver cirrhosis (%)	3 (4.02)	2 (5.41)	1
HCV RNA (log10 IU/mL)	6.2 (5.3, 6.6)	6.0 (5.2, 6.4)	0.0831
HBsAg+ (%)	6 (8.11)	2 (5.41)	0.7165
WBC (1000/u)	5.8 (4.9, 7.2)	6.1 (5.5, 7.8)	0.4546
Hemoglobin (g/dL)	14.7 (13.3, 15.8)	15.3 (14.4, 16.2)	0.0929
Platelet (1000/u)	194.5 (158.0, 235.0)	198.0 (172.0, 232.0)	0.8267
Creatinine (mg/dL)	0.9 (0.8, 1.0)	0.9 (0.8, 1.0)	0.9897
PT (seconds)	11.6 (11.0, 11.9)	11.3 (11.1, 11.8)	0.3687
INR	1.0 (1.0, 1.1)	1.0 (1.0, 1.1)	0.824
Albumin (g/dL)	4.3 (4.0, 4.5)	4.4 (4.2, 4.6)	0.0128
ALT (IU/L)	55.0 (40.0, 149.0)	38.0 (26.0, 64.0)	0.0028
AST (IU/L)	40.5 (29.0, 77.0)	30.0 (23.0, 44.0)	0.0026
Total bilirubin (mg/dL)	0.7 (0.5, 0.9)	1.0 (0.7, 1.3)	0.0004
Direct bilirubin (mg/dL)	0.3 (0.2, 0.4)	0.4 (0.3, 0.5)	0.0223
AFP (ng/mL)	5.9 (4.0, 8.9)	5.1 (4.3, 8.0)	0.5948
Treatment options (%)			<0.0001
Epclusa (sofosbuvir/velpatasvir)	47 (63.51)	8 (21.62)
Maviret (glecaprevir/pibrentasvir)	27 (36.49)	29 (78.38)

Data are presented as the median (IQ1, IQ3). Categorical variables were reported as counts and percentages. Abbreviations: HCV: hepatitis C virus; HBV: hepatitis B virus; RNA; ribonucleic acid; ALT: alanine aminotransferase; AST: aspartate aminotransferase; WBC: white blood cell; AFP: alpha-fetoprotein.